Chemomab director granted 8,621 ADS options

Chemomab Therapeutics Ltd. director Gwen A. Melincoff reported an initial option holding in American Depositary Shares.

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. director Gwen A. Melincoff reported an initial option holding in American Depositary Shares. She holds a stock option covering 8,621 underlying ADS with an exercise price of $1.86 per share, granted on June 1, 2026.

The option vests and becomes exercisable in equal monthly installments over a 36‑month period starting on June 1, 2026, and expires on June 1, 2036. This filing is an initial statement of beneficial ownership rather than a market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Melincoff Gwen A

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to buy American Depositary Shares)	--	--	--

Holdings After Transaction: Stock option (right to buy American Depositary Shares) — 8,621 contracts (Direct)

Footnotes (1)

1. F1. The option reported in this row was granted to the Reporting Person by the Issuer on June 1, 2026 and vests and becomes exercisable in equal monthly installments over a 36-month period, commencing on June 1, 2026.

Key Figures

Underlying ADS: 8,621 shares Exercise price: $1.86 per share Vesting period: 36 months +2 more

5 metrics

Underlying ADS 8,621 shares Underlying American Depositary Shares for reported stock option

Exercise price $1.86 per share Stock option exercise price

Vesting period 36 months Equal monthly vesting starting June 1, 2026

Grant date June 1, 2026 Option granted to reporting person

Expiration date June 1, 2036 Option expiration

Key Terms

American Depositary Shares, Stock option (right to buy American Depositary Shares), vests and becomes exercisable, beneficial ownership

4 terms

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Stock option (right to buy American Depositary Shares) financial

"security_title: "Stock option (right to buy American Depositary Shares)""

vests and becomes exercisable financial

"vests and becomes exercisable in equal monthly installments over a 36-month period"

beneficial ownership financial

"This filing is an initial statement of beneficial ownership rather than a market purchase or sale."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Chemomab (CMMB) director Gwen Melincoff report on this Form 3?

Gwen A. Melincoff reported an initial holding of a stock option over 8,621 American Depositary Shares of Chemomab Therapeutics. The option represents compensation, not an open‑market trade, and establishes her starting derivative position as a director.

What are the key terms of Gwen Melincoff’s Chemomab (CMMB) stock option?

The stock option covers 8,621 underlying American Depositary Shares at an exercise price of $1.86 per share. It was granted on June 1, 2026, and expires on June 1, 2036, giving a 10‑year exercise window from grant date.

How does Gwen Melincoff’s Chemomab (CMMB) option vest over time?

The option granted to Gwen Melincoff vests and becomes exercisable in equal monthly installments over 36 months. Vesting starts on June 1, 2026, meaning the award gradually becomes exercisable over three years rather than all at once on the grant date.

Is the Chemomab (CMMB) Form 3 by Gwen Melincoff a share purchase or sale?

The Form 3 does not show a market purchase or sale. It reports a granted stock option over 8,621 American Depositary Shares as part of her compensation, establishing beneficial ownership of this derivative position instead of reflecting an open‑market trade.

What type of security is reported in Gwen Melincoff’s Chemomab (CMMB) Form 3?

The filing reports a derivative security: a stock option giving the right to buy American Depositary Shares of Chemomab Therapeutics. The option’s underlying security is 8,621 ADS, exercisable at $1.86 per share under the stated vesting schedule and expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Melincoff Gwen A

(Last) (First) (Middle)

C/O CHEMOMAB THERAPEUTICS LTD.

10 HABARZEL ST. BUILDING C, 10TH FLOOR

(Street)

TEL AVIV 6158101

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy American Depositary Shares)	06/01/2026(1)	06/01/2036	American Depositary Shares	8,621	$1.86	D

Explanation of Responses:

1. The option reported in this row was granted to the Reporting Person by the Issuer on June 1, 2026 and vests and becomes exercisable in equal monthly installments over a 36-month period, commencing on June 1, 2026.

	/s/ Gwen Melincoff	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)